Combination of Pulsed Radiofrequency with Continuous Radiofrequency Thermocoagulation at Low Temperature Improves Efficacy and Safety in V2/V3 Primary Trigeminal Neuralgia

Yuanyuan Ding, MD, PhD1, Hongxi Li, MM1, Tao Hong, MM1, Yongqiang Zhu, MM1, Peng Yao, MD, PhD1, and Guangyu Zhou, MD, PhD2

Background: Primary trigeminal neuralgia (TN) is a common clinical refractory neuralgia. Severe pain is experienced during episodes, severely impacting the patient’s quality of life. Long-term suffering from the disease can lead to anxiety, depression, and even suicide. The pathological processes involved in TN are complex, the mechanisms of pathogenesis are unknown, and effective treatment is lacking.

Objective: This study aimed to assess the efficacy and safety of computed tomography (CT)-guided pulsed radiofrequency (PRF) combined with low-temperature continuous radiofrequency (CRF) thermocoagulation in V2/V3 primary trigeminal neuralgia.

Study Design: This research used a retrospective comparative study design.

Setting: The research took place at Shengjing Hospital of China Medical University.

Methods: A total of 80 hospitalized patients with TN were selected between January 2014 and December 2015 and randomly assigned to 2 groups differentiated by therapeutic method: CRF (CRF group, n = 40) and PRF + CRF (PCRF group, n = 40). Radiofrequency therapy was performed under the guidance of CT. Follow-up measures assessed preoperative conditions, pain remission, complications and side effects, recovery time, and recurrence rate over the 2 years following the surgery.

Results: The Visual Analog Scale (VAS) scores decreased in both groups after surgery. After one month, the decrease in the VAS score in the PCRF group was more apparent, and this difference was maintained for 2 years. The total efficiency rates in the CRF and PCRF groups were 85% and 97.5%, respectively, at 6 months, 1 year, and 2 years post surgery. The differences in total efficiency rate of pain between the 2 groups at 6 months, 1 year, and 2 years were statistically significant. Recovery times in the PCRF group were shorter than those in the CRF group. Specifically, recovery times for facial numbness in the CRF and PCRF groups were 3.12 ± 1.21 months and 2.23 ± 1.02 months, respectively. Recovery times for masticatory muscle weakness were 4.33 ± 1.54 months and 3.42 ± 0.98 months, respectively.

Limitations: This study is limited by being a retrospective study, and by having a relatively small sample size from a single center.

Conclusions: CT-guided PRF combined with low-temperature CRF thermocoagulation for treating V2/V3 primary TN effectively relieves pain, increases late-stage pain remission rate, reduces complications, and reduces the rate of recurrence.

Key words: Complication, continuous radiofrequency thermocoagulation, pulsed radiofrequency, recurrence rate, trigeminal neuralgia, Visual Analog Scale

Pain Physician 2018; 21:E545-E553
Pain Physician: September/October 2018: 21:E545-E553

Primary trigeminal neuralgia (TN) is a common clinical refractory neuralgia. It manifests as unilateral single or multiple distributions, brief recurrent episodes, lightning-like or acupuncture-like pain, existence of “trigger points,” and periodic and intermittent attacks. Severe pain experienced during these episodes can have a severe impact on a patient’s quality of life. Long-term suffering from the disease can lead to anxiety, depression, and even suicide (1,2). Epidemiological studies have shown that the prevalence of primary TN is about 12.6–28.9 cases per 10 million and increases with age (3). The pathological processes involved in TN are complex, the mechanisms of pathogenesis are unknown, and effective treatment is lacking.

The treatment of primary TN is divided mainly into drug therapy and surgical treatment, with drug therapy being the preferred approach. Surgical treatment should be considered when drug therapy is ineffective or drug-induced side effects are intolerable; surgical treatments include neurosurgical craniotomy, microvascular decompression, minimally invasive radio-frequency surgery, drug damage (alcohol injection or glycerol rhizotomy), and balloon compression (4-6). Radiofrequency therapy is characterized by small trauma, strong controllability, high safety, accuracy, and repeatability. It is considered a minimally invasive intervention for treating primary TN and has been widely applied (7). The temperature range for continuous radiofrequency (CRF) is 75–95°C, and it has a satisfactory pain remission rate. At a higher temperature, however, the occurrence of neural injury side effects (e.g., numbness) is higher. The pulsed radiofrequency (PRF) generates current at a temperature not exceeding 42°C. Therefore, it produces only a permanent regulatory effect on the nerve with almost no nerve damage. PRF does, however, have shortcomings such as a high recurrence rate and slow clinical effects. Due to its special anatomical location at V1, both efficiency and safety should be taken into account in selecting treatment parameters. A previous study explored and reported the radiofrequency treatment for V1 TN (8). Therefore, the CT-guided PRF combined with CRF thermocoagulation at low temperature was selected for this study as the treatment for V2/V3 primary TN, and its clinical effects were observed; secondary and V1 TN were excluded from this study.

Currently, many reports are available about the treatment of TN with radiofrequency (7,8,10). However, the patterns and parameters of radiofrequency vary across studies. There is no consistent standard for treating TN. This study aimed to explore effective treatment methods for V2/V3 primary TN with regard to efficiency, duration of efficient maintenance, complications, and recovery time, with the goal of guiding clinical practice.

Methods

Patients

From January 2014 to December 2015, 80 hospitalized patients with TN were selected from the Department of Pain Treatment within the medical university-affiliated hospital (Fig. 1). The study was approved by the ethics committee of the medical university-affiliated hospital, and all patients were preoperatively informed about the risks and complications. Patients enrolled in the study met the diagnostic criteria for primary TN in the third edition of the International Classification of Headache Disorders (9). In addition, patients had to meet the following inclusion criteria: (1) age > 30 years; (2) lesions of single V2 or V3 branch distribution, or combined V2 and V3 branch distribution; (3) moderate-to-severe pain as indicated by an average pain intensity score 24 hours before admission of > 5 points on the Visual Analog Scale (VAS); (4) natural course having lasted more than 3 months; and (5) history of standard drug treatment in the earlier stage, during which pain was not alleviated by oral medications such as carbamazepine, or side effects were intolerable. The exclusion criteria were as follows: (1) secondary TN, as determined by routine head and trigeminal nerve magnetic resonance imaging examination before surgery; (2) TN with V1 branch lesion, due to the risk and complications associated with the V1 branch; (3) local infection in the puncture area; (4) mental illness, mental retardation, or unconsciousness; (5) serious liver, kidney, heart, or lung diseases; and (6) coagulation dysfunction before surgery and local anesthetic drug allergy. Patients were screened according to inclusion and exclusion criteria and randomly assigned to 2 groups: CRF (CRF group, n = 40) and PRF + CRF (PCRF group, n = 40).

Surgical Procedure

Patients in the CRF group (n = 40) underwent CRF at 68°C for 180 seconds. Patients in the PCRF group underwent PRF at 42°C for 600 seconds, followed by CRF at 68°C for 180 seconds. Venous access was established preoperatively, and ceftriaxone sodium (Shanghai Roche Pharmaceuticals Co. Ltd., China) was administered intravenously 30 minutes before surgery to prevent infection.
Patients were placed in a supine position. Under the guidance of computed tomography (CT), the electrode plate of the radiofrequency equipment was attached to the ipsilateral shoulder. Patients' vital signs were intraoperatively monitored. The pre-ganglion semilunar approach was applied and the position confirmed at 2.5–3 cm lateral to the corner of the mouth on the affected side. The layer-by-layer infiltration anesthesia was performed with 0.5% lidocaine. Under the guidance of computed tomography (CT), the radiofrequency needle was used to puncture along the established angle and path to the foramen ovale. The CT scan was performed again for confirmation. The direction of the needle was further adjusted to the semilunar ganglion. The radiofrequency equipment (Baylis Medical, Montreal, Canada) was connected for the following tests: (1) sensation was tested at 50 Hz and 0.1–0.3 V to observe whether it could induce abnormal pain feeling consistent with presurgery and (2) movement was tested at 2 Hz and 0.1 V. The submandibular muscle jumped if V3 was affected. The surgeon then observed whether the radiofrequency needle had reached a predetermined position and whether the area of movement and pain after stimulation covered the preoperative site. The position of the needle tip was adjusted until the area of movement and sensation were completely covered, without affecting the normal area. Local anesthesia with 0.2 mL of 1.5%–2% lidocaine was performed after the needle reached the desired location. The CRF temperature was gradually increased from 50°C to the target temperature (50°C-55°C-60°C-68°C) over 180 seconds. The CRF group underwent CRF at 68°C for 180 seconds; the PCRF group underwent PRF at 42°C for 600 seconds followed by CRF at 68°C for 180 seconds. The patients' response was observed during the surgery, and the range was determined at all the times. The eyelash reflex was assessed to avoid V1 branch injury. The patients were urged to stay in bed for 24 hours after surgery and observed for 2–3 days.

**Observations and Follow-up**

Preoperative data including age, gender, course of disease, location of pain, preoperative Visual Analog Scale (VAS) score, and dose of antiepileptic drugs were
recorded. Follow-up evaluation was performed on the first day and at the end of the first week, first month, third month, sixth month, first year, and second year after surgery. Patients were followed up by nonsurgical group medical staff using the double-blind method. To measure pain, the VAS was used; scoring ranged from 0 points (no pain) to 10 points (the most unbearable pain). Degree of pain relief was assessed according to the World Health Organization’s evaluation criteria for pain relief; efficacy was categorized into 4 grades according to subjective symptoms and clinical signs exhibited by the patients, as assessed at different times. The 4 levels of pain relief efficacy are as follows: (a) complete remission (CR), indicating complete resolution of pain; (b) partial remission (PR), indicating significant resolution of pain (50-75%); (c) mild remission (MR), indicating partial resolution of pain (< 50%); and (d) no response (NR), indicating no resolution of pain. The significant efficiency rate (%) is equivalent to \((\text{CR} + \text{PR})/n\) × 100%. The total efficiency rate (%) is equivalent to \((\text{CR} + \text{PR} + \text{MR})/n\) × 100%.

In addition, incidence of complications and side effects were measured; these included short-term local bleeding, nausea and vomiting, headache, long-term facial numbness, decreased corneal reflex, and masticatory muscle weakness. Finally, recovery time from long-term side effects as well as recurrence rate was measured.

**Statistical Analysis**

Statistical analysis was performed using SPSS Version 19.0 (IBM Corporation, Armonk, NY). The normality of distribution was evaluated using the Kolmogorov–Smirnov test. Variables with a normal distribution were compared using a one-way analysis of variance, and values were presented as means ± standard deviations (SD). For variables with an abnormal distribution, the Kruskal–Wallis test was used for comparison, and values were presented as medians (interquartile range). Categorical variables were presented as frequencies and analyzed using the chi-square or Fisher exact test, as appropriate. Two-sided \(P\) values < 0.05 were considered to be statistically significant.

**Results**

**Needle Position on CT Scan and 3-Dimensional Reconstruction**

All patients underwent surgery successfully. The needle tip could be seen located in the foramen ovale on the CT scan plane, and the needle’s path in the foramen ovale was verified by 3-dimensional reconstruction (Fig. 2).

**Patient Characteristics**

Basic preoperative conditions were compared between the 2 groups. No significant differences in gen-

---

Fig. 2. (A) CT scan showed that the needle was located in the left foramen ovale, indicated by the arrow; (B) Three-dimensional reconstruction showed the needle and its path located in the left foramen ovale, indicated by the arrow.
PRF with RF Thermocoagulation Improves the Efficacy and Safety in Trieminal Neuralgia

Table 1. Preoperative patient characteristics in the 2 groups.

<table>
<thead>
<tr>
<th>Parameters</th>
<th>CRF</th>
<th>PCRF</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patients (n)</td>
<td>40</td>
<td>40</td>
</tr>
<tr>
<td>Gender (Women/Men, %)</td>
<td>25 (62.5)/15 (37.5)</td>
<td>26 (65.0)/14 (35.0)</td>
</tr>
<tr>
<td>Age (Yrs, Range)</td>
<td>56.42 ± 9.31 (33–73)</td>
<td>55.83 ± 10.64 (34–76)</td>
</tr>
<tr>
<td>Presurgery Pain Duration (M, Range)</td>
<td>10.5 ± 6.42 (6–23)</td>
<td>10.7 ± 6.26 (5–25)</td>
</tr>
<tr>
<td>Pain Side (n, %)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Right</td>
<td>22 (55.0)</td>
<td>21 (52.5)</td>
</tr>
<tr>
<td>Left</td>
<td>16 (40.0)</td>
<td>17 (42.5)</td>
</tr>
<tr>
<td>Both</td>
<td>2 (5.0)</td>
<td>2 (5.0)</td>
</tr>
<tr>
<td>Branches Affected (n, %)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>V2</td>
<td>12 (30.0)</td>
<td>11 (27.5)</td>
</tr>
<tr>
<td>V3</td>
<td>13 (32.5)</td>
<td>14 (35.0)</td>
</tr>
<tr>
<td>V2 V3</td>
<td>15 (37.5)</td>
<td>15 (37.5)</td>
</tr>
<tr>
<td>Presurgery VAS</td>
<td>7.43 ± 1.72</td>
<td>7.60 ± 1.82</td>
</tr>
<tr>
<td>Presurgery Drug Dosage</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Carbamazepine (mg/day, n)</td>
<td>554.43 ± 82.31 (22)</td>
<td>545.23 ± 79.86 (24)</td>
</tr>
<tr>
<td>Gabapentin (g/day, n)</td>
<td>2.01 ± 0.33 (9)</td>
<td>2.23 ± 0.41 (8)</td>
</tr>
<tr>
<td>Pregabalin (mg/day, n)</td>
<td>421.23 ± 72.47 (9)</td>
<td>426.21 ± 76.41 (8)</td>
</tr>
</tbody>
</table>

CRF, continuous radiofrequency; PCRF, pulsed combined continuous radiofrequency; VAS, Visual Analog Scale. Data are presented as numbers (%) of patients or mean ± SD.

under, age, duration of preoperative pain, pain location, affected nerves, preoperative VAS score, or dose of antiepileptic drugs (e.g., carbamazepine) were found between the groups (P > 0.05) (Table 1).

Pain Score

The VAS scores were significantly lower in both groups compared to pre-surgery scores (P < 0.05). At one month, the VAS score in the PCRF group was significantly lower than that of the CRF group. By 6 months, the VAS score had increased in the CRF group, while the duration of pain relief was longer in the PCRF group. The VAS score in the PCRF group was significantly lower than that of the CRF group in the later stages of follow-up and remained significantly lower at each time point from 1 month to 2 years (P < 0.05) (Fig. 3).

Degree of Pain Relief

Pain relief was observed immediately in both groups, one day after surgery, with significant pain relief after one week. The pain relief was effective for patients in both groups at discharge. The significant efficacy rate in the PCRF group was higher than that in the CRF group, but this difference was not statistically significant (P > 0.05). The total efficacy rates in the CRF group and PCRF group were 85% and 97.5%, respectively, after 6 months, 1 year, and 2 years; these differences were statistically significant (P < 0.05) (Table 2).

Complications and Side Effects

The surgeries were completed within 30 minutes in patients of both groups during hospitalization. Local bleeding, nausea, vomiting, and headache, which occurred in both groups after surgery, were quickly recovered after local cold compress, symptomatic treatment, and placement of patients in an absolute supine position. No serious adverse reactions were observed. The main side effects were facial numbness, weakness of masticatory muscles, and weakened corneal reflex. Different degrees of numbness after surgery occurred in all patients and were gradually recovered or reduced within one year. No permanent facial paralysis was observed after surgery. The incidence of weakened corneal reflex was quite low. One case of weakened corneal reflex in each group was recovered to normal within one month. No other more serious or permanent complications and side effects were observed. No significant difference in the incidence of facial numbness,
weakness of masticatory muscles, or weakened corneal reflex was observed between the 2 groups \((P > 0.05)\) (Table 3).

**Recovery Time for Long-Term Side Effects**

The recovery times for facial numbness in the CRF group and PCRF group were 3.12 ± 1.21 and 2.23 ± 1.02 (months), respectively. The recovery times for masticatory muscle weakness in the 2 groups were 4.33 ± 1.54 and 3.42 ± 0.98 (months), respectively. The recovery time for complications in the PCRF group was shorter than that in the CRF group, and the difference was statistically significant \((P < 0.05)\) (Table 4).

**Recurrence Rate**

The postoperative recurrence rates in the CRF group and PCRF group were 20.0% (8/40) and 5.0% (2/40), respectively, within 2 years after surgery. The recurrence rate in the PCRF group was lower than that in the CRF group, and the difference was statistically significant \((P < 0.05)\).

**Discussion**

The pathology and pathogenesis of primary TN are unknown. Moreover, clinically effective treatment for TN is lacking. Therefore, a treatment method with less trauma and fewer side effects is urgently needed. PRF and CRF thermocoagulation have been widely recognized for their success rate, efficacy, safety, and patient satisfaction \((10,11)\), and have gradually become one of the mainstream approaches to treating TN.

At present, radiofrequency thermocoagulation is the most effective minimally invasive technique.

![Image of VAS scores comparison](image_url)
for treating TN. It involves high-temperature effects of high-frequency current on the semilunar ganglia. The protein of small nerve fibers (Aδ- and C-type fibers) for pain transmission is coagulated and denatured (12). The action potential is hindered, and the purpose of analgesia is achieved (13). Therefore, the temperature is vital in achieving efficacy and lowering recurrence rate after thermal coagulation. Tang et al (14) compared the effects of low (< 75°C) and high temperatures (> 80°C) in treating TN and found no significant difference in the long-term painless rate between the 2 groups. However, side effects such as numbness were severe and lasted for a long time in the high-temperature group. Yao et al (15) compared effects in the low-temperature group (62, 65, and 68°C), but the recurrence rate was significantly increased with 62°C and 65°C. A previous study found that the 68°C radiofrequency coagulation had fewer complications and achieved a higher level of satisfaction compared with 75°C (16). In that study, PRF was intermittent (pulse frequency was 2 Hz) with 300–500 kHz current, which was released in 20-ms-short intermittent pulses, and then in 480-ms-long intermittent silent phases; this method was able to make the heat spread, and the effect of nerve damage was quite low (17). In a prospective, randomized, double-blind study, Erdine et al (18) used semilunar ganglion PRF (42°C, 2 Hz, 120 s) to treat TN. The short-term remission rate was only 10%. All of the patients relapsed after 3 months. The treatment effect was relatively poor, and the recurrence rate significantly increased. Finally, continuous radiofrequency thermocoagulation treatment was performed in all patients.

It is generally believed that the effect of pure PRF treatment in TN needs discussion, which is why the present study included no separate PRF group. It was necessary to find a therapeutic method that would not only destroy the fibers carrying pain and warm sensations, but that would not affect the function of the tactile fibers, while reducing complications. Luo et al (19,20) found that increasing the voltage of pulsed radiofrequency could effectively increase the remission rate of PRF in treating TN. However, the recurrence rate was still high. Our study further supports the conclusion that PRF treats the TN through its electric field effects rather than through temperature effects. PRF combined with low-temperature continuous radiofrequency thermocoagulation was used in this study to combine the advantages of the 2 treatment methods. It was observed that the pain was significantly relieved

<table>
<thead>
<tr>
<th>Complications and Side Effects</th>
<th>Group</th>
<th>CRF</th>
<th>PCRF</th>
</tr>
</thead>
<tbody>
<tr>
<td>Facial hematoma, n (%)</td>
<td>6 (15.0)</td>
<td>7 (17.5)</td>
<td></td>
</tr>
<tr>
<td>Nausea and vomiting, n (%)</td>
<td>1 (2.5)</td>
<td>0 (0.0)</td>
<td></td>
</tr>
<tr>
<td>Intracranial hypotension headache, n (%)</td>
<td>2 (5.0)</td>
<td>1 (2.5)</td>
<td></td>
</tr>
<tr>
<td>Facial numbness, n (%)</td>
<td>40 (100.0)</td>
<td>40 (100.0)</td>
<td></td>
</tr>
<tr>
<td>Masticatory muscle weakness, n (%)</td>
<td>9 (22.5)</td>
<td>10 (25.0)</td>
<td></td>
</tr>
<tr>
<td>Decreased corneal reflex, n (%)</td>
<td>1 (2.5)</td>
<td>1 (2.5)</td>
<td></td>
</tr>
</tbody>
</table>

CRF, continuous radiofrequency; PCRF, pulsed combined continuous radiofrequency

<table>
<thead>
<tr>
<th>Side Effects</th>
<th>Group</th>
<th>CRF</th>
<th>PCRF</th>
</tr>
</thead>
<tbody>
<tr>
<td>Facial numbness</td>
<td>3.12 ± 1.21</td>
<td>2.23 ± 1.02*</td>
<td></td>
</tr>
<tr>
<td>Masticatory muscle weakness</td>
<td>4.33 ± 1.54</td>
<td>3.42 ± 0.98*</td>
<td></td>
</tr>
</tbody>
</table>

CRF, continuous radiofrequency; PCRF, pulsed combined continuous radiofrequency. Compared with CRF, *P < 0.05
within the tissue. The tissue is then heated, the local temperature is increased, and the nerves are damaged for therapeutic purposes. The high temperature can cause cell apoptosis and necrosis. The eschar produced at 80°C can cause significant damage to neurons and nerve fibers (21,22). The PRF current is intermittently generated for dissipation of heat. In a study by Pohajsky et al, histological examination showed that 42°C PRF on dorsal root ganglions and sciatic nerves in rats resulted in transient neuroendothelial edema and collagenous deposits with no structural changes (23). Erdine et al found axon ultrastructural damage, abnormal membrane and mitochondria, and collapse of microtubules and microfilaments as observed under the electron microscope (24). In a study by Tun et al, the myelin structure in the myelinated axon was destroyed (25). However, all of these changes were reversible. Further, 42°C was considered as the temperature boundary to observe whether the tissue damage was reversible. In other words, the analgesic effect of PRF was not achieved by damaging the nerve, but possibly through neuromodulation (26,27). Studies have shown that the effects of PRF may be at the microscopic or even subcellular levels (28). Higuchi et al (29) and Van Zundert et al (30) found that PRF could induce c-fos gene (immediate early gene) upregulation in the neurons of laminas I, II, and IV of the spinal dorsal horn. Hamann et al (31) found that PRF significantly increased the expression of activating transcription factor 3 in the rat dorsal root ganglion. Cahana et al (32) found, through in vivo experiments, that PRF could regulate the synaptic plasticity of nerve cells. At the cytokine levels, PRF could upregulate the expression of glia cell line-derived neurotrophic factor (33), decrease the presynaptic release of glutamate and citrulline (34), and induce spinal descending inhibitory pathways via 5-hydroxytryptamine 3 and α2 receptors (35). However, Choi et al (36) found that the expression of inflammatory proteins in the PRF and CRF groups was upregulated. The upregulated expression of inflammatory cytokines in the PRF group returned to normal after one month. However, the expression in the CRF group continuously and significantly increased. The PRF group showed only mild axonal injury and some mitochondrial swelling, but the CRF group showed irreversible changes in the ultrastructure of sciatic nerve fibers. It was therefore believed that PRF-induced pain relief might be due to the temporary blockage of neural signals by reversible neurons through the nerve conduction pathway, whereas CRF-induced pain relief might be achieved by the permanent blockage of neural signals through other neural pathways. The present study found that PCRF treatment can promote recovery from side effects in the later stage and effectively reduce the recurrence rate, which might be related to the slow regulation effect of neuromodulation signals. Our findings are consistent with previous reports that the combination of PRF and CRF helped in eliminating postoperative complications and side effects (37).

**Conclusions**

In summary, CT-guided PRF combined with low-temperature CRF thermocoagulation for treating V2/V3 primary TN can effectively relieve pain, increase the pain remission rate in the late stage, reduce complications, and reduce the recurrence rate. Hence, it may be a choice for treating TN.

**References**

9. Headache Classification Committee


